Momelotinib treatment‐emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis

• Published in: British journal of haematology 2015-04, Vol.169 (1), p.77-80
• Main Authors: Abdelrahman, Ramy A., Begna, Kebede H., Al‐Kali, Aref, Hogan, William J., Litzow, Mark R., Pardanani, Animesh, Tefferi, Ayalew
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Benzamides - administration & dosage; Benzamides - adverse effects; Female; Humans; Janus Kinase 1 - antagonists & inhibitors; Janus Kinase 2 - antagonists & inhibitors; Male; Middle Aged; momelotinib; myelofibrosis; myeloproliferative; neuropathy; Peripheral Nervous System Diseases - chemically induced; Peripheral Nervous System Diseases - enzymology; Peripheral Nervous System Diseases - epidemiology; Prevalence; Primary Myelofibrosis - drug therapy; Primary Myelofibrosis - enzymology; Primary Myelofibrosis - epidemiology; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Risk Factors
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/bjh.13262

Summary Momelotinib (a JAK1 and JAK2 inhibitor) induces both anaemia and spleen responses in myelofibrosis (MF). Momelotinib treatment‐emergent peripheral neuropathy (TE‐PN) was documented in 44 (44%) of 100 MF patients treated at our institution; median time of TE‐PN onset was 32 weeks and duration 11 months. Improvement after drug dose reduction or discontinuation was documented in only two patients. TE‐PN was significantly associated with treatment response (P = 0·02) and longer survival (P = 0·048) but significance was lost during multivariate analysis that included treatment duration. TE‐PN did not correlate with initial or maximum momelotinib dose or previous treatment with JAK inhibitor or thalidomide.